To the Editor We read the results of the Optimize-2 trial by Hortobagyi et al1 with keen interest. After 9 or more doses of monthly zoledronic acid or pamidronate, 416 women with breast cancer with bone metastases were randomized to receive zoledronic acid once every 4 weeks (4W) or zoledronic acid once every 12 weeks (12W) for 1 year. The results showed that the 12W zoledronic acid was noninferior to 4W zoledronic acid dosing.
Shapiro CL, Himelstein AL. Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. JAMA Oncol. 2018;4(4):585–586. doi:10.1001/jamaoncol.2017.0789
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: